SLS - SELLAS Life Sciences Group Inc
IEX Last Trade
1.29
-0.010 -0.775%
Share volume: 535,683
Last Updated: Fri 30 Aug 2024 09:59:53 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.30
-0.01
-0.77%
View ratios
| Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | |
|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | |
| Report Date | 2022-05-12 | 2022-08-11 | 2022-11-14 | 2023-03-16 | |
| Assets | |||||
| Total Assets | 21.434 M | 32.210 M | 26.001 M | 20.943 M | |
| Current Assets | 17.839 M | 28.737 M | 22.605 M | 17.756 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 2.487 M | 1.650 M | 1.157 M | 531.000 K | |
| Short Term Investments | 2.487 M | 1.650 M | 1.157 M | 531.000 K | |
| Total Receivables | 1.000 M | 0.000 | 0.000 | 0.000 | |
| Current Cash | 14.252 M | 26.987 M | 21.348 M | 17.125 M | |
| Total Non-current Assets | 3.595 M | 3.473 M | 3.396 M | 3.187 M | |
| Property Plant Equipment | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Assets | 554.000 K | 514.000 K | 521.000 K | 399.000 K | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 1.914 M | 1.914 M | 1.914 M | 1.914 M | |
| Liabilities and shareholders’ equity | |||||
| Total Liabilities and shareholders’ equity | 21.434 M | 32.210 M | 26.001 M | 20.943 M | |
| Total liabilities | 17.409 M | 13.153 M | 13.404 M | 16.092 M | |
| Total current liabilities | 10.679 M | 12.186 M | 12.553 M | 15.515 M | |
| Accounts Payable | 2.842 M | 3.339 M | 2.127 M | 3.357 M | |
| Other liabilities | 5.847 M | 184.000 K | 171.000 K | 4.000 K | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 5.847 M | 184.000 K | 171.000 K | 4.000 K | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 4.025 M | 19.057 M | 12.597 M | 4.851 M | |
| Common stock | 15.897 M | 20.287 M | 20.562 M | 20.836 M | |
| Retained earnings | -155.347 M | -163.761 M | -170.783 M | -179.904 M |